Anti-Fibrotic Drug Discovery

Erscheinungsjahr 2020
ISBN: 978-1-78801-510-3
Verlag: RSC Publishing

Buch, Englisch, 356 Seiten, Format (B × H): 157 mm x 234 mm, Gewicht: 726 g

Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.

Autoren/Hrsg.

Brenneman, Jehrod

Iyer, Malliga R

Fachgebiete

• Naturwissenschaften Chemie Organische Chemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie

Inhaltsverzeichnis

TGFß Signaling;

Targeting the av Integrins in Fibroproliferative Disease;

Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators;

Autotaxin Inhibitors in Fibrosis;

Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology;

Targeting the Ubiquitin Proteasome System in Pulmonary Fibrosis;

Galectin-3 Involvement in Fibrotic Diseases;

Emerging Role of CXCR4 in Fibrosis;

BH3 Mimetic Drugs for Anti-fibrotic Therapy;

Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities;

Targeting Fibroblasts in Fibrosis and Cancer